Pooled data from two studies indicates that the serotonin-noradrenaline reuptake inhibitor (SNRI) venlafaxine XR has significantly better anxiolytic activity than placebo in the short-term treatment of generalised social anxiety disorder (SAD).
This finding was reported here at the 15th Congress of the European College of Neuropsychopharmacology (ECNP).
Venlafaxine significantly reduced the overall symptoms of generalised SAD as well as fear and avoidance factors in social and performance settings, noted lead investigator Richard Mangano, PhD, clinical researcher at Wyeth Research in Collegeville, Pennsylvania. At 12 weeks, he added, 47 percent of the subjects responded to venlafaxine XR compared to 32 percent receiving placebo.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!